title: [Clinical efficacy and safety of trastuzumab plus capecitabine as first-line therapy for HER-2 positive metastatic breast cancer].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of trastuzumab plus capecitabine as first-line therapy for HER-2-positive metastatic breast cancer patients who have previously received anthracyclines and taxanes.
  
  
  METHODS
  The patients who have HER-2-positive breast cancer recurrence and metastasis after treated by anthracyclines and taxanes were enrolled in this study. The patients received trastuzumab (6 mg/kg every 21 days following a loading dose of 8 mg/kg on cycle 1) and capecitabine (2 000 mg/m², days 1 to 14 every 21 days).
  
  
  RESULTS
  38 patients were enrolled. The median PFS for trastuzumab plus capecitabine was 8.6 months. The objective response rate (ORR) was 31.6%. Clinical benefit rate (CBR) was 65.8%. The most serious adverse event was leucopenia in one patient. Relatively common hematology toxicity was grade I or II leucopenia and neutropenia. The most common nonhematologic toxicity was hand-foot syndrome (HFS), which observed in 8 patients (21%). The morbidity of grade II and III HFS were 8% and 3% respectively.
  
  
  CONCLUSIONS
  Trastuzumab plus capecitabine is an effective and safe regimen as first-line treatment for HER-2-positive metastatic breast cancer patients whose cancer is resistant to treatment with anthracyclines and taxanes.
authors.affiliation: Department of Breast Cancer, 307 Hospital of PLA, Clinical College of Anhui Medical University, Beijing 100071, China.
authors.forename: Wang
authors.initials: W
authors.lastname: Li
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
authors.forename: Li
authors.initials: L
authors.lastname: Bian
authors.forename: Shaohua
authors.initials: S
authors.lastname: Zhang
authors.forename: Huiqiang
authors.initials: H
authors.lastname: Zhang
authors.forename: Jinmei
authors.initials: J
authors.lastname: Zhou
authors.forename: Santai
authors.initials: S
authors.lastname: Song
authors.affiliation: Email: jiangzf@hotmail.com.
authors.forename: Zefei
authors.initials: Z
authors.lastname: Jiang
mesh_terms: D018943:Anthracyclines; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms; D019496:Cancer Vaccines; D000069287:Capecitabine; D006801:Humans; D009362:Neoplasm Metastasis; D018719:Erb-b2 Receptor Tyrosine Kinases; D012008:Recurrence; D043823:Taxoids; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D019496:Cancer Vaccines; D000069287:Capecitabine; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab; C508053:ERBB2 protein, human